Paras Biopharmaceuticals enhances integrated control systems & bioprocess automation for continuous manufacturing

With a potential to achieve greater product quality and shorter time to market, Paras Biopharmaceuticals is focused on integrated control systems and bioprocess automation aimed towards continuous bio-manufacturing. The company has made substantial progress toward zero or minimal hold time, in between processes, while superior bioprocess knowledge and greater understanding of biological processes is expected to achieve reduced costs of biologics production. This significantly enhances the company’s objective to bring affordable healthcare costs to biologics and biosimilar development.

Paras Biopharmaceuticals Finland Oy is an Oulu-based company having niche expertise in the production of microbial-based biopharmaceutical materials. Since its inception in 2012, the company has developed a robust portfolio of bioprocess technologies for the efficient biomanufacturing of complex and “difficult to do” biologics for rare and orphan diseases.

Contract development & microbial biologics manufacturing (CDMO)

Offers end-to-end services to produce microbial recombinant proteins from early-stage (20L), scale-up (150L) to large-scale (750L).

Development of biosimilar technologies and partnership

Actively engaged in R&D and is offering partnership for further development (including clinical development) on Recombinant Teriparatide (Forteo® Biosimilar), Recombinant IL1-RA / Anakinra (Kineret® Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (Nplate® Biosimilar). * Further biologics are in the pipeline.

Development of Recombinant expression systems and process technologies for biologics

Due to its own portfolio of proprietary technologies: Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant®, the company has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars and biologics.

Recombinant Bioprocess Enzymes

Has developed and is offering recombinant bioprocess enzymes used in the cleavage of fusion proteins including Recombinant Enterokinase & Tev Protease.

Paras Biopharmaceuticals Infrastructure in Finland: Activities emanate from its fully owned biologics development and production facility in Oulu. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying. The team has strong experience in carrying out microbial biologics production and is ready to cater to any biopharma needs for scale-up & commercial scale production.

For further information, visit the website or contact the company at

Source: Paras Biopharmaceuticals